Second, since excessive expression of HSP22 is associated with cardiac hypertrophy, utilizing drugs that inactivate the kinase activity of HSP22 may prevent cardiac hypertrophy, such as proteasome inhibitors [37]. Here, HSPB8 is linked to cardiac hypertrophy.